The MEK/ERK inhibitors exerted mild or even stimulatory effects on dendritic cells, CD4+ T cells, and tumor antigen-specific CD8+ T cells[42], but inhibitory effects on infiltrations of regulatory T cells and monocyte/macrophages [43]. The gene discussed is CD4; the disease is neoplasm.